SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, a new recently emerged sarbecovirus. This virus uses the human ACE2 enzyme as receptor for cell entry, recognizing it with the receptor binding domain (RBD) of the S1 subunit of the viral spike protein. We present the use of phage...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoglio, Federico, Meier, Doris, Langreder, Nora, Steinke, Stephan, Rand, Ulfert, Simonelli, Luca, Heine, Philip Alexander, Ballmann, Rico, Schneider, Kai-Thomas, Roth, Kristian Daniel Ralph, Ruschig, Maximilian, Riese, Peggy, Eschke, Kathrin, Kim, Yeonsu, Schäckermann, Dorina, Pedotti, Mattia, Kuhn, Philipp, Zock-Emmenthal, Susanne, Wöhrle, Johannes, Kilb, Normann, Herz, Tobias, Becker, Marlies, Grasshoff, Martina, Wenzel, Esther Veronika, Russo, Giulio, Kröger, Andrea, Brunotte, Linda, Ludwig, Stephan, Fühner, Viola, Krämer, Stefan Daniel, Dübel, Stefan, Varani, Luca, Roth, Günter, Čičin-Šain, Luka, Schubert, Maren, Hust, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952403/
https://www.ncbi.nlm.nih.gov/pubmed/33707427
http://dx.doi.org/10.1038/s41467-021-21609-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952403/
https://www.ncbi.nlm.nih.gov/pubmed/33707427
http://dx.doi.org/10.1038/s41467-021-21609-2

Ejemplares similares